SCHEMBL6014673

SCHEMBL6014673

N#CC1(c2ccc(NC(=O)c3ccccc3NCc3ccncc3)cc2)CCCC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.76
MAP3K20 Q9NYL2 1/20 0.76
RIPK3 Q9Y572 1/20 0.76
KDR P35968 12/20 0.70
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
LMNA P02545 2/20 0.60
TP53 P04637 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
FLT1 P17948 5/20 0.54
KIT P10721 4/20 0.54
BRAF P15056 2/20 0.54
ABL1 P00519 2/20 0.52
CSF1R P07333 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014721 0.99 RET (0.75) RETMAP3K20RIPK3KDRNPC1
SCHEMBL6014513 0.98 RET (0.73) RETMAP3K20RIPK3KDRNPC1
SCHEMBL6014604 0.96 RET (0.70) RETMAP3K20RIPK3KDRNPC1
Rivoceranib SCHEMBL29360856 0.87 RET (1.00) RETMAP3K20RIPK3KDRNPC1
Rivoceranib SCHEMBL1814966 0.87 RET (1.00) RETMAP3K20RIPK3KDRNPC1
SCHEMBL6014666 0.86 RET (0.98) RETMAP3K20RIPK3KDRNPC1
SCHEMBL6014575 0.85 RET (0.96) RETMAP3K20RIPK3KDRNPC1
Rivoceranib SCHEMBL21847695 0.83 KDR (1.00) RETMAP3K20RIPK3KDRNPC1
SCHEMBL6014552 0.82 RET (0.93) RETMAP3K20RIPK3KDRFLT1
SCHEMBL6014656 0.82 KDR (0.56) RETMAP3K20RIPK3KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP claimed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US claimed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US claimed
EP-1633712-B1 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2014-06-25 EP disclosed
US-7129252-B2 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2006-10-31 US disclosed
EP-1633712-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Chen, Guoqing Paul (US) 2006-03-15 EP disclosed
WO-2005000232-A2 SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS CHEN GUOQING PAUL (US) 2005-01-06 WO disclosed
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors HLB CO., LTD. (KR) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259916-A1 Six membered amino-amide derivatives an angiogenisis inhibitors TEK, FLT1, VEGFA RET 2382/4885MAP3K20 2688/4885RIPK3 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.